Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference

Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX), a late-stage biotechnology firm focused on therapies for autoimmune diseases, will participate in the Cantor Oncology & HemOnc Conference on September 28, 2022. President and CEO Rachelle Jacques will address challenges in cell therapy during a panel at 9:00 a.m. Eastern time and will engage in 1:1 meetings with investors. Akari’s lead treatment, nomacopan, is under Phase 3 trials for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, along with preclinical work on PAS-nomacopan for geographic atrophy.

NEW YORK and LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the investor-focused Cantor Oncology & HemOnc Conference on September 28, 2022. President and CEO Rachelle Jacques will take part in a conference panel, Addressing Challenges in Cell Therapy and Transplant, at 9:00 a.m. Eastern time and will attend 1:1 investor meetings.

About Akari Therapeutics

Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari’s lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of C5 complement activation and leukotriene B4 (LTB4) activity. Akari’s pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), as well as pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit akaritx.com.

Investor Contact:
Mike Moyer
LifeSci Advisors
(617) 308-4306
mmoyer@lifesciadvisors.com

Media Contact:
Eliza Schleifstein
Schleifstein PR   
(917) 763-8106
eliza@schleifsteinpr.com

FAQ

What is Akari Therapeutics presenting at the Cantor Oncology & HemOnc Conference?

Akari Therapeutics will present on challenges in cell therapy during a panel discussion at the Cantor Oncology & HemOnc Conference on September 28, 2022.

Who is the CEO of Akari Therapeutics?

The CEO of Akari Therapeutics is Rachelle Jacques.

What are the main therapies developed by Akari Therapeutics?

Akari Therapeutics is developing nomacopan, a treatment for autoimmune diseases, which is in Phase 3 trials for hematopoietic stem cell transplant-related thrombotic microangiopathy.

When will Akari Therapeutics participate in investor meetings?

Akari Therapeutics will participate in 1:1 investor meetings during the Cantor Oncology & HemOnc Conference on September 28, 2022.

What is the focus of Akari's investigational therapy nomacopan?

Nomacopan is focused on inhibiting C5 complement activation and leukotriene B4 activity for autoimmune and inflammatory diseases.